Comparative table of the clinical and biological characteristics of the 2 patients
| . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age, y | 47 | 76 |
| Sex | Male | Female |
| Eastern Cooperative Oncology Group scale | 0 | 0 |
| B symptoms | No | No |
| Lymph nodes affected | 2 sides of the diaphragm | 2 sides of the diaphragm |
| Splenomegaly | No | No |
| Extranodal involvement | No | Gastrointestinal infiltration |
| PB expression | Yes | Yes |
| BM involvement | Yes | Yes |
| Ann Arbor stage | IV | IV |
| Hemoglobin (g/L) | 116 | 120 |
| Platelets (× 109/L) | 60 | 234 |
| Leucocytes | ||
| Global count (× 109/L) | 6.86 | 12.7 |
| Neutrophils (× 109/L) | 1.5 | 4.2 |
| Lymphocytes (× 109/L) | 4.92 | 7.8 |
| Monoclonal gammopathy | No | IgM |
| Increased lactate dehydrogenase | No | No |
| Increased β2 microglobulin | No | No |
| HIV | Negative | Negative |
| HBV; HCV | Positive HB core antibody, negative HB surface antigen; HCV negative | Positive HB core antibody, negative HB surface antigen; HCV negative |
| Immunophenotype | CD19++, CD20++, CD79b+, CD23+, CD25+, CD5+, BCL2+++, kappa restriction CD10−, CD11c−, CD103−, CD123−, CD200−, BCL6−, cyclin D1−, SOX11− | CD19++, CD20++, CD79b+, CD5−, CD11c+, BCL2+++, kappa restriction CD10−, CD23−, CD103−, CD123−, CD200−, cyclin D1− |
| Ki67 (%) | 10-20 | 5 |
| Cytogenetics | ||
| Karyotype | 46,XY,t(3;17)(q27;q21)[10]/46,XY[10] | 46,XX,t(3;17)(q27;q21)[15]/46,XX[5] |
| FISH, IGF2BP2:LSM12 | Positive in 60% of the nuclei | Positive in 58% of the nuclei |
| FISH, IGH:CCND1 | Negative | Negative |
| FISH, BCL6 (3q27) SPLIT | Negative | Negative |
| Single nucleotide polymorphism array | No copy number alterations or loss of heterozygosis | No copy number alterations or loss of heterozygosis |
| OGM | Not done | IGF2BP2::LSM12 |
| MYD88 | Not mutated | Not mutated |
| CXCR4 | CXCR4 Ser341PhefsTer3 mutation | Not mutated |
| WGS | CXCR4 Ser341PhefsTer3 mutation IGF2BP2::LSM12 | Not done |
| . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age, y | 47 | 76 |
| Sex | Male | Female |
| Eastern Cooperative Oncology Group scale | 0 | 0 |
| B symptoms | No | No |
| Lymph nodes affected | 2 sides of the diaphragm | 2 sides of the diaphragm |
| Splenomegaly | No | No |
| Extranodal involvement | No | Gastrointestinal infiltration |
| PB expression | Yes | Yes |
| BM involvement | Yes | Yes |
| Ann Arbor stage | IV | IV |
| Hemoglobin (g/L) | 116 | 120 |
| Platelets (× 109/L) | 60 | 234 |
| Leucocytes | ||
| Global count (× 109/L) | 6.86 | 12.7 |
| Neutrophils (× 109/L) | 1.5 | 4.2 |
| Lymphocytes (× 109/L) | 4.92 | 7.8 |
| Monoclonal gammopathy | No | IgM |
| Increased lactate dehydrogenase | No | No |
| Increased β2 microglobulin | No | No |
| HIV | Negative | Negative |
| HBV; HCV | Positive HB core antibody, negative HB surface antigen; HCV negative | Positive HB core antibody, negative HB surface antigen; HCV negative |
| Immunophenotype | CD19++, CD20++, CD79b+, CD23+, CD25+, CD5+, BCL2+++, kappa restriction CD10−, CD11c−, CD103−, CD123−, CD200−, BCL6−, cyclin D1−, SOX11− | CD19++, CD20++, CD79b+, CD5−, CD11c+, BCL2+++, kappa restriction CD10−, CD23−, CD103−, CD123−, CD200−, cyclin D1− |
| Ki67 (%) | 10-20 | 5 |
| Cytogenetics | ||
| Karyotype | 46,XY,t(3;17)(q27;q21)[10]/46,XY[10] | 46,XX,t(3;17)(q27;q21)[15]/46,XX[5] |
| FISH, IGF2BP2:LSM12 | Positive in 60% of the nuclei | Positive in 58% of the nuclei |
| FISH, IGH:CCND1 | Negative | Negative |
| FISH, BCL6 (3q27) SPLIT | Negative | Negative |
| Single nucleotide polymorphism array | No copy number alterations or loss of heterozygosis | No copy number alterations or loss of heterozygosis |
| OGM | Not done | IGF2BP2::LSM12 |
| MYD88 | Not mutated | Not mutated |
| CXCR4 | CXCR4 Ser341PhefsTer3 mutation | Not mutated |
| WGS | CXCR4 Ser341PhefsTer3 mutation IGF2BP2::LSM12 | Not done |
HBV, hepatitis B virus; HCV, hepatitis C virus.